Last reviewed · How we verify
XP
Xenon gas is used as an anesthetic for its sedative and amnestic properties.
Xenon gas is used as an anesthetic for its sedative and amnestic properties. Used for General anesthesia for surgical procedures.
At a glance
| Generic name | XP |
|---|---|
| Sponsor | Epidemiological and Clinical Research Information Network |
| Drug class | anesthetic gas |
| Modality | Small molecule |
| Therapeutic area | Anesthesiology |
| Phase | FDA-approved |
Mechanism of action
Xenon's mechanism of action is not fully understood, but it is thought to work by modulating the activity of NMDA receptors in the brain, leading to sedation and amnesia. It also has a high blood-gas partition coefficient, which allows it to rapidly induce anesthesia.
Approved indications
- General anesthesia for surgical procedures
Common side effects
- Respiratory depression
- Hypotension
- Nausea and vomiting
Key clinical trials
- Examination of Clinical and Laboratory Abnormalities in Patients With Defective DNA Repair: Xeroderma Pigmentosum, Cockayne Syndrome, or Trichothiodystrophy
- A Single-Blind Randomized Controlled Study Comparing the Efficacy of High-Intensity Laser Therapy and Focused Extracorporeal Shock Wave Therapy in Patients With Plantar Fasciitis (NA)
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) (PHASE3)
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension (PHASE3)
- Investigation of the Relationship Between Gray and White Matter Volumes, Walking Exercise, and Body Fat Percentage in Adults With a Body Mass Index Above 25 (NA)
- Coblation and Traditional Adenoidectomy: A Comparative Study (NA)
- The Effect of Different Irrigation Methods Used During Endodontic Treatment on Postoperative Pain in Teeth With Periapical Lesions (NA)
- Fatigue Alleviation Through Neuromodulating Therapy in Multiple Sclerosis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- XP CI brief — competitive landscape report
- XP updates RSS · CI watch RSS
- Epidemiological and Clinical Research Information Network portfolio CI